Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit

Critical Care Medicine

Volumn 37, Issue 4, 2009, Pages 1463-1469

  Shorr, Andrew F ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Bacterial drug resistance; Costs and cost analysis; Gram negative bacterial infections; Intensive care units; Length of stay; Mortality

Indexed keywords

ACINETOBACTER; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; GRAM NEGATIVE INFECTION; HOSPITAL COST; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; MORTALITY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

COSTS AND COST ANALYSIS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; TREATMENT OUTCOME;

EID: 67650457718     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819ced02     Document Type: Review

References (32)

1. Gaynes R, Edwards JR: Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-854
2. Obritsch MD, Fish DN, MacLaren R, et al: National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48:4606-4610
3. Paterson DL, Ko WC, Von Gottberg A, et al: International prospective study of Klebsiella pneumoniae bacteremia: Implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140:26-32
4. Schwaber MJ, Carmeli Y: Mortality and delay in effective therapy associated with extendedspectrum beta-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913-920
5. Giske CG, Monnet DL, Cars O, et al: Clinical and economic impact of common multidrugresistant gram-negative bacilli. Antimicrob Agents Chemother 2008; 52:813-821
6. Raymond DP, Pelletier SJ, Crabtree TD, et al: Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 2003; 31:1035-1041
7. Evans HL, Lefrak SN, Lyman J, et al: Cost of Gram-negative resistance. Crit Care Med 2007; 35:89-95
8. Kwa AL, Low JG, Lee E, et al: The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis 2007; 58:99-104
9. Cosgrove SE, Kaye KS, Eliopoulous GM, et al: Health and economic outcomes of the emergence of third-generation cephalospo-rin resistance in Enterobacter species. Arch Intern Med 2002; 162:185-190
10. Lautenbach E, Patel JB, Bilker WB, et al: Extended-spectrum beta-lactamase-produc-ing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-1171
11. Lee SY, Kotapati S, Kuti JL, et al: Impact of extended-spectrum beta-lactamase-produc-ing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: A matched cohort study. Infect Control Hosp Epidemiol 2006; 27:1226-1232
12. Tumbarello M, Spanu T, Sanguinetti M, et al: Bloodstream infections caused by extendedspectrum-beta-lactamase-producing Klebsiella pneumoniae: Risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50:498-504
13. Marra AR, Wey SB, Castelo A, et al: Nosocomial bloodstream infections caused by Klebsiella pneumoniae: Impact of extendedspectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis 2006; 6:24
14. Bhavnani SM, Ambrose PG, Craig WA, et al: Outcomes evaluation of patients with ESBL-and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: Report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006; 54:231-236
15. Skippen I, Shemko M, Turton J, et al: Epidemiology of infections caused by extendedspectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: A nested case-control study from a tertiary hospital in London. J Hosp Infect 2006; 64:115-123
16. Pena C, Pujol M, Ardanuy C, et al: An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase. J Hosp Infect 2001; 47:53-59
17. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al: Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50: 43-48
18. Cao B, Wang H, Sun H, et al: Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004; 57:112-118
19. Bukholm G, Tannaes T, Kjelsberg AB, et al: An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect Control Hosp Epidemiol 2002; 23: 441-446
20. Lautenbach E, Weiner MG, Nachamkin I, et al: Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27:893-900
21. Gasink LB, Fishman NO, Weiner MG, et al: Fluoroquinolone-resistant Pseudomonas aeruginosa: Assessment of risk factors and clinical impact. Am J Med 2006; 119:526 e519-e525
22. Gasink LB, Fishman NO, Nachamkin I, et al: Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2007; 28:1175-1180
23. Combes A, Luyt CE, Fagon JY, et al: Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med 2006; 32:1970-1978
24. Ortega B, Groeneveld AB, Schultsz C: Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epidemiol 2004; 25:825-831
25. Kwon KT, Oh WS, Song JH, et al: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007; 59:525-530
26. Sunenshine RH, Wright MO, Maragakis LL, et al: Multidrug-resistant Acinetobacter infection mortality rate and length of hospital-ization. Emerg Infect Dis 2007; 13:97-103
27. Lee NY, Lee HC, Ko NY, et al: Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007; 28:713-719
28. Kollef KE, Schramm GE, Wills AR, et al: Predictors of thirty-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134:281-287
29. Shorr AF, Micek ST, Kollef MH: Inappropriate therapy for methicillin-resistant Staphylococcus aureus: Resource utilization and cost implications. Crit Care Med 2008; 36: 2335-2340
30. Soo Hoo GW, Wen YE, Nguyen TV, et al: Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 2005; 128:2778-2787
31. Garcia JC, Ferreira Filho OF, Grion CM, et al: Impact of the implementation of a therapeutic guideline on the treatment of nosocomial pneumonia acquired in the intensive care unit of a university hospital. J Bras Pneumol 2007; 33:175-184
32. Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012